Shenzhen Zhongjia Biomedical Technology Co., Ltd. Shenzhen Zhongjia Biomedical Technology Co., Ltd.

Company News

Company News

Great News! Another Zhongjia Medium Gets FDA DMF Filing

2026-7-23

  Recently, Shenzhen Zhongjia Biomedical Technology Co., Ltd. (“Zhongjia Biomedical”) delivered good news again – its self-developed serum-free hematopoietic stem cell basal medium has officially obtained a Drug Master File (DMF) filing issued by the U.S. Food and Drug Administration (FDA), with filing number 044283. This is the fourth medium product from Zhongjia Biomedical to receive an FDA DMF filing, marking another step forward in our R&D and compliance capabilities for critical raw materials used in cell therapy, and providing global customers with higher-quality, more compliant supply chain options.

  Filing Overview
DMF Number: 044283
Filing Type: Type II
Product Name: Serum-free hematopoietic stem cell basal medium
Applications: Hematopoietic stem cell expansion, culture, and cell therapy-related research and applications

  Core Product Highlights
Serum-free formulation: avoids batch differences and safety risks caused by animal-derived components, making it more suitable for clinical-grade applications.
Efficient expansion support: validated to stably support ex vivo expansion and functional maintenance of hematopoietic stem cells.
Compliance first: the DMF filing will help customers cite relevant data during FDA submissions, accelerating IND, NDA and other approval processes.

  Continuous Dedication, Empowering the Industry
As a leading domestic supplier of cell culture raw materials, Zhongjia Biomedical stays committed to the principles of “technical excellence and quality safety”, continuously launching core raw materials that meet international standards. To date, four of our medium products have received FDA DMF filings, covering key application directions such as mesenchymal stem cells, immune cells, and hematopoietic stem cells. We understand that the success of cell therapy products relies on stable, traceable, and compliant raw material support.

  Zhongjia Biomedical will continue to provide compliant, stable and efficient medium solutions for cell therapy enterprises worldwide.

الأخبار ذات الصلة

  • التركيز على MLD: لماذا ينبغي الكشف عن هذا الحثل الشحمي الأبيض النادر في وقت أبكر؟

    2026-10-23

  • هل يمكن تقليل خطر ألزهايمر؟ منظمة الصحة العالمية تحدد عوامل خطر الخرف القابلة للتأثير

    2026-9-28

  • علاج ألزهايمر يتقدم: من الأميلويد إلى تاو واستراتيجيات الأهداف المتعددة

    2026-9-28

  • تطورات جديدة في تحرّي ألزهايمر: اختبار الدم يتصدر اهتمام الأبحاث

    2026-9-28

  • خبر كبير! وسيط آخر من Zhongjia يحصل على إدراج FDA-DMF

    2026-7-23